Vikas Lifecare

Why is Vikas Lifecare Ltd falling/rising?

As of 30-Aug, Vikas Lifecare Ltd's stock price is stable at 1.35, with a recent short-term gain of 13.33% due to increased investor participation. However, the long-term outlook is negative, with a year-to-date decline of 23.73% and significant financial concerns, making it a risky investment choice.

As of 30-Aug, Vikas Lifecare Ltd's stock price is currently stable at 1.35, showing no change (0.00%). However, the stock has experienced a notable rise over the past five days, gaining 13.33% during this period. This recent upward movement can be attributed to several factors, including a significant increase in investor participation, as evidenced by a 64.29% rise in delivery volume compared to the five-day average.<BR><BR>Despite this short-term gain, the stock has a concerning long-term outlook. Year-to-date, it has declined by 23.73%, and over the past year, it has fallen by 39.46%. The company's financial health is also a concern, with operating losses and a negative EBITDA of Rs. -48.34 crore. Additionally, the company's ability to service its debt is weak, reflected in a poor EBIT to Interest ratio of -2.33. <BR><BR>While the company reported positive quarterly results in March 2026, including a 738.1% growth in PAT and the highest net sales recorded, these improvements are overshadowed by its overall weak long-term fundamental strength and consistent underperformance against benchmarks over the last three years. Thus, while there is a short-term rise in stock price, the long-term outlook remains negative, indicating that the stock is risky and may not be a strong investment choice.

Which are the latest news on Vikas Lifecare?

Who are in the management team of Vikas Lifecare?

The management team of Vikas Lifecare includes Arvind Gupta (CFO), Anil Kumar, Ruby Bansal, Parul Rai (Company Secretary), Vijay Kumar Sharma (CEO), Sundeep Kumar Dhawan (Managing Director), Richa Sharma, and Chandan Kumar (Director & CFO), who oversee the company's operations and strategy.

The management team of Vikas Lifecare includes the following individuals:<BR><BR>1. **Arvind Gupta** - Director (Finance) & CFO<BR>2. **Anil Kumar** - Independent Director<BR>3. **Ruby Bansal** - Independent Director<BR>4. **Parul Rai** - Company Secretary & Compliance Officer<BR>5. **Vijay Kumar Sharma** - Director & Chief Executive Officer<BR>6. **Sundeep Kumar Dhawan** - Managing Director<BR>7. **Richa Sharma** - Independent Director<BR>8. **Chandan Kumar** - Director & CFO<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Vikas Lifecare do?

Vikas Lifecare Ltd specializes in recycling plastic waste and manufacturing polymer compounds. As of March 2026, it reported net sales of ₹169 Cr and a net profit of ₹42 Cr, with a market cap of ₹234 Cr.

Overview: <BR>Vikas Lifecare Ltd operates in the recycling of plastic waste and the trading and manufacturing of polymer compounds within the Trading & Distributors industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Vikas Lifecare Limited was originally incorporated as Vikas Multicorp Limited in 1995. The company changed its name to Vikas Lifecare Limited on April 09, 2021, following a Special Resolution and the issuance of a fresh Certificate of Incorporation. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 169 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 42 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 234 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 13.00 <BR>Industry P/E: 14 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.19 <BR>Return on Equity: 3.34% <BR>Price to Book: 0.42 <BR><BR>Contact Details: <BR>Address: G 1 34/1 East Punjabi Bagh, Vikas Apartments, New Delhi, Delhi: 110026 <BR>Tel: 91-011-40450110 <BR>Email: info@vikasmulticorp.com <BR>Website: http://www.vikaslifecarelimited.com

Who are the peers of the Vikas Lifecare?

Vikas Lifecare's peers include Chandrima Mercan, Sakuma Exports, Sicagen India, Chemkart India, Northern Spirits, Signet Industrie, Maximus Interna., and Amrapali Inds. Vikas Lifecare has below-average management risk and growth, with a 1-year return of -44.49%, while Amrapali Inds. leads with a 145.98% return.

Peers: The peers of Vikas Lifecare are Chandrima Mercan, Sakuma Exports, Sicagen India, Chemkart India, Northern Spirits, Signet Industrie, Maximus Interna., and Amrapali Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at Chandrima Mercan and Chemkart India, while Average management risk is found at Sakuma Exports, Sicagen India, Northern Spirits, Signet Industrie, Maximus Interna., and the rest. Below Average management risk is present at Vikas Lifecare and Amrapali Inds. Growth is Excellent at Chandrima Mercan and Amrapali Inds, while Below Average growth is noted at Vikas Lifecare, Sakuma Exports, Sicagen India, Signet Industrie, and the rest. Average growth is seen at Maximus Interna. Capital Structure is Excellent at Chemkart India, Good at Sakuma Exports, while Below Average is observed at Vikas Lifecare, Sicagen India, Northern Spirits, Signet Industrie, Amrapali Inds, and the rest.<BR><BR>Return Snapshot: Amrapali Inds. has the highest 1-year return at 145.98%, while Sakuma Exports has the lowest at -35.88%. Vikas Lifecare's 1-year return of -44.49% is lower than both. Additionally, peers such as Sakuma Exports, Sicagen India, and Northern Spirits have negative six-month returns.

How big is Vikas Lifecare?

As of 14th August, Vikas Lifecare Ltd has a market capitalization of 234.07 Cr, with recent Net Sales of 499.36 Cr and a Net Profit of 18.41 Cr.

As of 14th August, Vikas Lifecare Ltd has a market capitalization of 234.07 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vikas Lifecare reported Net Sales of 499.36 Cr and a Net Profit of 18.41 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 531.76 Cr and Total Assets of 724.76 Cr.

Should I buy, sell or hold Vikas Lifecare Ltd?

Are Vikas Lifecare Ltd latest results good or bad?

Vikas Lifecare Ltd's latest results show significant challenges, with a net profit of ₹41.57 crores overshadowed by an operating loss of ₹26.28 crores and a negative cash flow of ₹222 crores, indicating ongoing struggles despite a 73.78% increase in net sales. Overall, the financial health of the company remains concerning.

The latest results for Vikas Lifecare Ltd present a mixed picture, but overall, they indicate significant challenges. In Q4 FY26, the company reported a consolidated net profit of ₹41.57 crores, which might seem positive at first glance. However, this figure is misleading due to a substantial operating loss of ₹26.28 crores, resulting in an operating margin of -15.59%. This marks the lowest operating margin in seven quarters, highlighting severe operational difficulties.<BR><BR>While net sales surged by 73.78% quarter-on-quarter to ₹168.62 crores, this growth did not translate into profitability. The company continues to struggle with negative cash flows and a return on equity of -0.66%, indicating that it is destroying shareholder value rather than creating it. Furthermore, the year-on-year comparison reveals a staggering decline of 1533.45% in net profit compared to Q4 FY25.<BR><BR>The operational challenges are compounded by a negative cash flow from operations of ₹222 crores in FY25, raising concerns about the company's ability to sustain its business model. The volatility in revenues and persistent losses suggest that Vikas Lifecare is facing significant hurdles that could hinder any potential recovery.<BR><BR>In summary, while there are signs of revenue growth, the underlying financial health of Vikas Lifecare Ltd is concerning, leading to the conclusion that the latest results are more indicative of ongoing struggles rather than a turnaround.

When is the next results date for Vikas Lifecare Ltd?

The next results date for Vikas Lifecare Ltd is February 7, 2026.

The next results date for Vikas Lifecare Ltd is scheduled for February 7, 2026.

How has been the historical performance of Vikas Lifecare?

Vikas Lifecare has experienced fluctuating financial performance, with net sales increasing to 480.02 Cr in March 2025, but profitability declining significantly, resulting in a net loss of -10.61 Cr. Despite growth in total assets, cash flow from operations has worsened, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Vikas Lifecare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Vikas Lifecare's net sales have generally increased, reaching 480.02 Cr in March 2025 from 445.75 Cr in March 2024, although it slightly decreased from 476.05 Cr in March 2023. The total operating income followed a similar trend, peaking at 480.02 Cr in March 2025. However, the total expenditure has also risen, amounting to 501.62 Cr in March 2025, which has led to an operating profit (PBDIT) of 4.36 Cr, a decline from 30.49 Cr in the previous year. The company reported a profit before tax of -6.95 Cr in March 2025, down from 17.58 Cr in March 2024, resulting in a profit after tax of -5.00 Cr. The consolidated net profit also fell to -10.61 Cr in March 2025 from 14.03 Cr in March 2024. The total assets of Vikas Lifecare increased to 724.76 Cr in March 2025, up from 554.70 Cr in March 2024, while total liabilities rose to 724.76 Cr from 554.70 Cr in the same period. Cash flow from operating activities showed a negative trend, with -222.00 Cr in March 2025 compared to -41.00 Cr in March 2024, indicating challenges in cash generation. Overall, while Vikas Lifecare has seen growth in sales and assets, profitability has been inconsistent, reflecting a complex financial landscape.

Is Vikas Lifecare overvalued or undervalued?

As of July 22, 2024, Vikas Lifecare is considered overvalued and risky, with a negative PE ratio of -46.72 and an EV to EBITDA of -25.23, significantly underperforming against the Sensex with a year-to-date return of -38.77%.

As of 22 July 2024, the valuation grade for Vikas Lifecare has moved from very expensive to risky, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE ratio of -46.72, an EV to EBITDA of -25.23, and a Price to Book Value of 0.89, which highlight the underlying financial challenges the company faces.<BR><BR>In comparison to its peers, Vikas Lifecare's valuation metrics are concerning, particularly when contrasted with industry standards. For instance, its PE ratio is significantly negative, while the EV to EBITDA ratio also reflects a troubling trend. Notably, the company has underperformed against the Sensex, with a year-to-date return of -38.77% compared to the Sensex's positive 5.56%. This performance further reinforces the notion that Vikas Lifecare is currently overvalued in the market.

What is the technical trend for Vikas Lifecare?

As of June 4, 2025, Vikas Lifecare's technical trend is bearish, supported by daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD, indicating a prevailing bearish market sentiment.

As of 4 June 2025, the technical trend for Vikas Lifecare has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the daily moving averages and Bollinger Bands both signaling bearish trends. The weekly MACD shows a mildly bullish signal, but this is countered by the monthly MACD and KST both being bearish. The Dow Theory indicates a mildly bearish trend on the weekly timeframe, while the monthly shows no trend. Overall, the indicators suggest a prevailing bearish sentiment in the market for Vikas Lifecare.

Who are the top shareholders of the Vikas Lifecare?

The top shareholders of Vikas Lifecare include promoter Vikas Garg with 13.1%, public shareholder Sylph Technologies at 3.1%, and individual investors holding 73.79%. There are also 18 Foreign Institutional Investors with a combined 0.46% stake, and no mutual funds currently hold shares.

The top shareholders of Vikas Lifecare include Vikas Garg, who is the promoter with the highest holding at 13.1%. The highest public shareholder is Sylph Technologies, holding 3.1%. Additionally, individual investors collectively hold a significant portion of the shares at 73.79%. The company also has 18 Foreign Institutional Investors (FIIs) with a combined holding of 0.46%. Notably, there are no mutual funds currently holding shares in the company.

Has Vikas Lifecare declared dividend?

No Dividend History Available